Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.
417 results
  • Screening of nanoemulsion components for asenapine maleate using validated RP-HPLC method. [Journal Article]
    Ann Pharm Fr. 2020 May 06 [Online ahead of print]Kumbhar SA, Kokare CR, … Gorain B
  • A novel, simple reversed-phase high-performance liquid chromatographic (RP-HPLC) analytical method was developed and validated for the quantitative determination of asenapine from various nanoemulsion components during pre-formulation screening. The developed method was validated according to ICH Q2 (R1) guidelines. The developed and validated method was precisely and accurately quantified asenap…
  • Asenapine in the Treatment of Bipolar Depression. [Journal Article]
    Psychopharmacol Bull. 2020 Mar 12; 50(1):8-18.El-Mallakh RS, Nuss S, … Adler C
  • CONCLUSIONS: While this is a very small sample, asenapine appears to have a beneficial effect on both depression and anxiety in depressed bipolar I patients compared to treatment with placebo. Due to the large fraction of subjects with the short form, the hypothesis that the SF-5HTTR might increase asenapine response could not be adequately tested.
  • Treatment of Mixed Features in Bipolar Disorder: an Updated View. [Review]
    Curr Psychiatry Rep. 2020 Feb 06; 22(3):15.Chakrabarty T, Keramatian K, Yatham LN
  • Mixed presentations in bipolar disorder have long posed clinical and nosological challenges. The DSM-5 mixed features specifier was developed to provide a more flexible and clinically relevant definition of mixed presentations compared with narrowly defined DSM-IV mixed episodes. However, there is little guidance on treating such presentations. Here, we summarize the evidence for biological treat…
  • [Evidence-based treatment of acute psychotic episode and schizophrenia in children and adolescents]. [Review]
    Zh Nevrol Psikhiatr Im S S Korsakova. 2019; 119(12):132-138.Ivashchenko DV, Buromskaya NI, … Sychev DA
  • Children and adolescents are a special group in the context of psychopharmacotherapy. Given the limited choice of registered antipsychotics permitted in childhood, caution should be exercised in the choice of medication. This literature review reviews the current evidence base for pharmacotherapy of acute psychotic episode and schizophrenia in children and adolescents. The results of major system…
  • Update on weight-gain caused by antipsychotics: a systematic review and meta-analysis. [Journal Article]
    Expert Opin Drug Saf. 2020 Mar; 19(3):295-314.Barton BB, Segger F, … Musil R
  • Introduction: Antipsychotic-induced weight-gain (AIWG) is a very important, yet often neglected side-effect in the treatment with first and second generation antipsychotics. AIWG can increase the risk of developing metabolic syndrome, diabetes and cardiovascular disease. Meta-analyzes mostly concentrate on AIWG in schizophrenic and bipolar patients, even though antipsychotics are prescribed off-l…
  • [German S3 guidelines on bipolar disorders-first update 2019 : What is new in pharmacotherapy?] [Review]
    Nervenarzt. 2020 Mar; 91(3):216-221.Bschor T, Baethge C, … Bauer M
  • CONCLUSIONS: The S3 guidelines make recommendations at the highest scientific level. In view of these findings, lithium is clearly underutilized for maintenance therapy. In the absence of clear contraindications (advanced renal insufficiency), every patient with bipolar disease should be given the chance of lithium prophylaxis for an adequately long period.
  • Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia. [Meta-Analysis]
    Am J Psychiatry. 2020 04 01; 177(4):342-353.Leucht S, Crippa A, … Davis JM
  • CONCLUSIONS: In chronic schizophrenia patients with acute exacerbations, doses higher than the identified 95% effective doses may on average not provide more efficacy. For some drugs, higher than currently licensed doses might be tested in further trials, because their dose-response curves did not plateau.
  • LiverTox: Clinical and Research Information on Drug-Induced Liver Injury: Asenapine [BOOK]
    . National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda (MD)BOOK
  • Asenapine is a second generation (atypical) antipsychotic agent that is taken sublingually and used in the treatment of schizophrenia and manic or mixed episodes associated with bipolar 1 disorder. Asenapine is associated with a low rate of transient and mild serum aminotransferase elevations during therapy, but has not been linked to instances of clinically apparent acute liver injury.
  • Transdermal Delivery of Antipsychotics: Rationale and Current Status. [Journal Article]
    CNS Drugs. 2019 09; 33(9):849-865.Abruzzo A, Cerchiara T, … Bigucci F
  • The aim of this article is to provide the rationale for the development of transdermal formulations of antipsychotics by highlighting their main advantages, starting with an overview of the antipsychotic formulations that are currently available on the market. Progress regarding transdermal antipsychotic formulations was investigated by performing a search of papers, patents and clinical trials p…
  • Asenapine: Pharmacological Aspects and Role in Psychiatric Disorders. [Review]
    Psychiatr Danub. 2019 Jun; 31(2):157-161.Reyad AA, Mishriky R
  • Schizophrenia and bipolar disorders are serious psychiatric disorders with substantial health risks. Asenapine is a new second-generation antipsychotic, available as a sublingual tablet, approved in Europe for the treatment of moderate-to-severe manic episodes in adults, and in US for manic or mixed episodes of bipolar I disorder in adults and adolescents. In this review, we searched the availabl…
  • Safety considerations in the psychopharmacology of pediatric bipolar disorder. [Review]
    Expert Opin Drug Saf. 2019 Sep; 18(9):777-794.Sun AY, Woods S, … Stepanova E
  • Introduction: The standard of treatment of pediatric bipolar disorder (BPD) often requires life-long psychopharmacological management. Several pharmacological agents are approved by the US FDA for the treatment of pediatric BPD. However, each medication may cause adverse events (AEs). Provider awareness of AE profiles of common pharmacologic agents would serve to better inform patients and famili…
New Search Next